Serum antibody levels as risk factors in the dissemination of herpes zoster
- PMID: 229783
Serum antibody levels as risk factors in the dissemination of herpes zoster
Abstract
Serum antibody levels against varicella-zoster virus (VZV) were examined by immune adherence hemagglutination assay (IAHA), indirect fluorescent antibody (IFA) assay, and complement fixation techniques in 67 immunocompromised patients with localized and disseminated herpes zoster. In the serum obtained initially, undetectable IAHA titers were found in 56.5% of the patients with disseminated zoster compared with 18.2% of those with localized zoster. When serum obtained within the first seven days of illness was analyzed, undetectable IAHA titers and IFA titers of less than 32 were noted in 77.8% of those with disseminated zoster but in only 18.5% of those with localized disease. Peak serum antibody titers in patients with disseminated zoster were eventually equal to or greater than those in localized zoster. The patient groups were comparable in age, underlying disease, and therapy, although Hodgkin's disease was more frequent in patients with disseminated zoster. Thus, the absent IAHA or low IFA levels of circulating antibody early in illness were highly significant risk factors in dissemination of virus in herpes zoster.
Similar articles
-
Comparison of 4 serological tests--complement fixation, neutralization, fluorescent antibody to membrane antigen and immune adherence hemagglutination--for assay of antibody to varicella-zoster (V-Z) virus.Biken J. 1979 Jun;22(2):55-60. Biken J. 1979. PMID: 231433
-
Detection of varicella-zoster antibody by immune adherence hemagglutination test.Southeast Asian J Trop Med Public Health. 1984 Sep;15(3):342-7. Southeast Asian J Trop Med Public Health. 1984. PMID: 6098021
-
Susceptibility to varicella-zoster virus in Thai children and young adults.Southeast Asian J Trop Med Public Health. 1985 Sep;16(3):414-20. Southeast Asian J Trop Med Public Health. 1985. PMID: 3006266
-
Varicella-zoster virus infections in the immunocompromised host. Natural history and treatment.Scand J Infect Dis Suppl. 1991;80:69-74. Scand J Infect Dis Suppl. 1991. PMID: 1666447 Review.
-
Zoster, a recrudescence of VZ virus infection.Postgrad Med J. 1970 Nov;46(541):653-8. doi: 10.1136/pgmj.46.541.653. Postgrad Med J. 1970. PMID: 4321947 Free PMC article. Review. No abstract available.
Cited by
-
High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis.Ann Rheum Dis. 1990 Aug;49(8):630-3. doi: 10.1136/ard.49.8.630. Ann Rheum Dis. 1990. PMID: 2168693 Free PMC article.
-
Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients.J Clin Microbiol. 2006 Dec;44(12):4441-3. doi: 10.1128/JCM.01312-06. Epub 2006 Oct 11. J Clin Microbiol. 2006. PMID: 17035500 Free PMC article.
-
Microbiology laboratory and the management of mother-child varicella-zoster virus infection.World J Virol. 2016 Aug 12;5(3):97-124. doi: 10.5501/wjv.v5.i3.97. World J Virol. 2016. PMID: 27563537 Free PMC article. Review.
-
Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine.NPJ Vaccines. 2024 Apr 4;9(1):72. doi: 10.1038/s41541-024-00865-5. NPJ Vaccines. 2024. PMID: 38575581 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources